Loading patent…
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsMasaaki Goto, Akihiro Tomoyasu, Kazuki Yano, Fumie Kobayashi, Nobuaki Nakagawa, Hisataka Yasuda, Kyoji Yamaguchi, Masahiko Kinosaki, Shin-ichi Mochizuki, Tadashi Nakakarumai, Tomonori Morinaga, Eisuke Tsuda, Kanji Higashio
Estimating the term…
A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.
A recombinant C-terminal deletion mutant protein having adipogenesis inhibitory activity, wherein the wild-type full-length protein to be truncated by C-terminal deletion is a polypeptide consisting of SEQ ID NO:
A recombinant polypeptide consisting of amino acid residues 1-265 of SEQ ID NO:
A recombinant polypeptide consisting of amino acid residues 1-235 of SEQ ID NO:
A recombinant polypeptide consisting of amino acid residues 1-205 of SEQ ID NO:
A recombinant polypeptide consisting of amino acid residues 1-175 of SEQ ID NO:
An isolated polypeptide consisting of amino acid residues 1-265 of SEQ ID NO:
Dependencies are inferred from the claim text.